Association Between Early Treatment With Tocilizumab and Mortality Among Critically Ill Patients With COVID-19

IMPORTANCE: Therapies that improve survival in critically ill patients with coronavirus disease 2019 (COVID-19) are needed. Tocilizumab, a monoclonal antibody against the interleukin 6 receptor, may counteract the inflammatory cytokine release syndrome in patients with severe COVID-19 illness. OBJEC...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Udgivet i:JAMA Intern Med
Main Authors: Gupta, Shruti, Wang, Wei, Hayek, Salim S., Chan, Lili, Mathews, Kusum S., Melamed, Michal L., Brenner, Samantha K., Leonberg-Yoo, Amanda, Schenck, Edward J., Radbel, Jared, Reiser, Jochen, Bansal, Anip, Srivastava, Anand, Zhou, Yan, Finkel, Diana, Green, Adam, Mallappallil, Mary, Faugno, Anthony J., Zhang, Jingjing, Velez, Juan Carlos Q., Shaefi, Shahzad, Parikh, Chirag R., Charytan, David M., Athavale, Ambarish M., Friedman, Allon N., Redfern, Roberta E., Short, Samuel A. P., Correa, Simon, Pokharel, Kapil K., Admon, Andrew J., Donnelly, John P., Gershengorn, Hayley B., Douin, David J., Semler, Matthew W., Hernán, Miguel A., Leaf, David E.
Format: Artigo
Sprog:Inglês
Udgivet: American Medical Association 2021
Fag:
Original Investigation
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC7577201/
https://ncbi.nlm.nih.gov/pubmed/33080002
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jamainternmed.2020.6252
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker